- Home
- INSM vs ACM Comparison
INSM vs ACM Comparison
Compare INSM & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ACM
- Stock Information
- Founded
- INSM 1988
- ACM 1980
- Country
- INSM United States
- ACM United States
- Employees
- INSM N/A
- ACM N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- INSM Health Care
- ACM Consumer Discretionary
- Exchange
- INSM Nasdaq
- ACM Nasdaq
- Market Cap
- INSM 17.3B
- ACM 14.7B
- IPO Year
- INSM 2000
- ACM 2007
- Fundamental
- Price
- INSM $102.68
- ACM $109.72
- Analyst Decision
- INSM Strong Buy
- ACM Strong Buy
- Analyst Count
- INSM 17
- ACM 8
- Target Price
- INSM $106.80
- ACM $119.88
- AVG Volume (30 Days)
- INSM 4.1M
- ACM 857.1K
- Earning Date
- INSM 08-07-2025
- ACM 08-04-2025
- Dividend Yield
- INSM N/A
- ACM 0.95%
- EPS Growth
- INSM N/A
- ACM N/A
- EPS
- INSM N/A
- ACM 4.58
- Revenue
- INSM $381,030,000.00
- ACM $16,047,510,000.00
- Revenue This Year
- INSM $28.03
- ACM $3.26
- Revenue Next Year
- INSM $120.54
- ACM $5.98
- P/E Ratio
- INSM N/A
- ACM $23.90
- Revenue Growth
- INSM 20.77
- ACM 4.55
- 52 Week Low
- INSM $60.40
- ACM $82.23
- 52 Week High
- INSM $102.70
- ACM $118.56
- Technical
- Relative Strength Index (RSI)
- INSM 78.76
- ACM 53.57
- Support Level
- INSM $98.46
- ACM $111.08
- Resistance Level
- INSM $102.00
- ACM $114.22
- Average True Range (ATR)
- INSM 3.50
- ACM 1.73
- MACD
- INSM 2.61
- ACM -0.48
- Stochastic Oscillator
- INSM 99.61
- ACM 31.19
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.